Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate

被引:40
作者
Kolli, M
Lastere, S
Schiffer, CA
机构
[1] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA
[2] Hop Bichat Claude Bernard, Virol Lab, F-75877 Paris 18, France
关键词
HIV-1; protease; drug resistance; co-evolution; p1-p6; D30N;
D O I
10.1016/j.virol.2005.11.049
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The selective pressure of the competitive protease inhibitors causes both HIV-1 protease and occasionally its substrates to evolve drug resistance. We hypothesize that this occurs particularly in substrates that protrude beyond the substrate envelope and contact residues that mutate in response to a particular protease inhibitor. To validate this hypothesis, we analyzed substrate and protease sequences for covariation. Using the chi(2) test, we show a positive correlation between the nelfinavir-resistant D30N/N88D protease mutations and mutations at the p1-p6 cleavage site as compared to the other cleavage sites. Both nelfinavir and the substrate p1-p6 protrude beyond the substrate envelope and contact residue 30, thus possibly making the p1-p6 cleavage site more vulnerable to co-evolution. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:405 / 409
页数:5
相关论文
共 14 条
[1]   Polymorphism of HIV type 1 Gag p7/p1 and p1/p6 cleavage sites: Clinical significance and implications for resistance to protease inhibitors [J].
Bally, F ;
Martinez, R ;
Peters, S ;
Sudre, P ;
Telenti, A .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (13) :1209-1213
[2]   Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors [J].
Doyon, L ;
Croteau, G ;
Thibeault, D ;
Poulin, F ;
Pilote, L ;
Lamarre, D .
JOURNAL OF VIROLOGY, 1996, 70 (06) :3763-3769
[3]   Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites [J].
Fehér, A ;
Weber, IT ;
Bagossi, P ;
Boross, P ;
Mahalingam, B ;
Louis, JM ;
Copeland, TD ;
Torshin, IY ;
Harrison, RW ;
Tözsér, J .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2002, 269 (16) :4114-4120
[4]   THE MIDAS DISPLAY SYSTEM [J].
FERRIN, TE ;
HUANG, CC ;
JARVIS, LE ;
LANGRIDGE, R .
JOURNAL OF MOLECULAR GRAPHICS, 1988, 6 (01) :13-&
[5]   Covariation of amino acid positions in HIV-1 protease [J].
Hoffman, NG ;
Schiffer, CA ;
Swanstrom, R .
VIROLOGY, 2003, 314 (02) :536-548
[6]   Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease [J].
Kaldor, SW ;
Kalish, VJ ;
Davies, JF ;
Shetty, BV ;
Fritz, JE ;
Appelt, K ;
Burgess, JA ;
Campanale, KM ;
Chirgadze, NY ;
Clawson, DK ;
Dressman, BA ;
Hatch, SD ;
Khalil, DA ;
Kosa, MB ;
Lubbehusen, PP ;
Muesing, MA ;
Patick, AK ;
Reich, SH ;
Su, KS ;
Tatlock, JH .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (24) :3979-3985
[7]   Resistance-associated loss of viral fitness in human immunodeficiency virus type 1:: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients [J].
Mammano, F ;
Petit, C ;
Clavel, F .
JOURNAL OF VIROLOGY, 1998, 72 (09) :7632-7637
[8]   Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure:: a randomized trial [J].
Meynard, JL ;
Vray, M ;
Morand-Joubert, L ;
Race, E ;
Descamps, D ;
Peytavin, G ;
Matheron, S ;
Lamotte, C ;
Guiramand, S ;
Costagliola, D ;
Brun-Vézinet, F ;
Clavel, F ;
Girard, PM .
AIDS, 2002, 16 (05) :727-736
[9]   Nelfinavir mesylate: A protease inhibitor [J].
Pai, VB ;
Nahata, MC .
ANNALS OF PHARMACOTHERAPY, 1999, 33 (03) :325-339
[10]   Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolate from patients treated with the protease inhibitor nelfinavir [J].
Patick, AK ;
Duran, M ;
Cao, Y ;
Shugarts, D ;
Keller, MR ;
Mazabel, E ;
Knowles, M ;
Chapman, S ;
Kuritzkes, DR ;
Markowitz, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (10) :2637-2644